JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN

JPMorgan Chase & Co. raised its stake in Urogen Pharma (NASDAQ:URGN) by 36.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 534,545 shares of the company’s stock after buying an additional 144,181 shares during the period. JPMorgan Chase & Co. owned about 1.16% of Urogen Pharma worth $10,664,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Osaic Holdings Inc. grew its position in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares in the last quarter. State of Wyoming bought a new stake in Urogen Pharma during the third quarter worth about $66,000. Strs Ohio bought a new stake in Urogen Pharma during the third quarter worth about $76,000. CWM LLC boosted its holdings in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after purchasing an additional 650 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $19.61 on Friday. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00. The firm has a market cap of $954.61 million, a PE ratio of -6.13 and a beta of 1.34. The business has a 50 day moving average price of $20.94 and a 200-day moving average price of $20.86.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The firm had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. Research analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Wall Street Analyst Weigh In

URGN has been the subject of several research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Monday. Finally, Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.29.

More Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Urogen’s quarterly report beat EPS expectations (smaller loss than forecast), prompting an early gap‑up in the shares as investors cheered the outcome. Read More.
• Positive Sentiment: D. Boral Capital assigned a “Buy” rating to URGN, which supports demand from investors looking for upside in the drug’s commercial rollout and can help short‑term sentiment. Read More.
• Neutral Sentiment: Coverage discusses UroGen weighing the commercial success of ENVISION and an expanded loan to support its bladder cancer push — this could fund growth but also increases leverage and execution risk, so the market reaction is ambiguous. Read More.
• Negative Sentiment: HC Wainwright substantially lowered near‑term EPS estimates: Q2 2026 to ($0.64) from ($0.42), Q3 2026 to ($0.42) from ($0.14), Q4 2026 to ($0.33) from $0.01, and cut FY2026 to ($1.99) from ($1.18). (They did slightly raise Q1 2026 to ($0.60) from ($0.63) and project FY2027 at $0.45.) These deeper downgrades to 2026 earnings signal weaker near‑term profitability expectations and are the main negative catalyst weighing on the stock. Read More.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. The trade was a 12.72% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by insiders.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.